Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Teva
Medtronic
Baxter
Federal Trade Commission
Mallinckrodt
Healthtrust
Chubb

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,350,468

« Back to Dashboard

Which drugs does patent 6,350,468 protect, and when does it expire?

Patent 6,350,468 protects PYLERA and is included in one NDA.

This patent has thirty-two patent family members in twenty-four countries.

Summary for Patent: 6,350,468
Title: Double capsule for the administration of active principles in multiple therapies
Abstract:A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms Helicobacter Pylori. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles. In a preferred embodiment of the invention, the pharmaceutical dosage form has an external capsule containing bismuth subcitrate and metronidazole, and an internal capsule containing tetracycline and optionally omeprazole, which is used in therapy for eradication of Helicobacter pylori.
Inventor(s): Sanso; Giovanni (Milan, IT)
Assignee: Axcan Pharma Inc. (Quebec, CA)
Application Number:09/581,721
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Drugs Protected by US Patent 6,350,468

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE ➤ Sign Up
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,350,468

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI97A2788Dec 17, 1997
PCT Information
PCT FiledDecember 14, 1998PCT Application Number:PCT/EP98/08167
PCT Publication Date:June 24, 1999PCT Publication Number: WO99/30693

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Deloitte
Medtronic
Argus Health
US Department of Justice
Daiichi Sankyo
Covington
Fuji
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.